Literature DB >> 18684813

Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Sanggu Kim1, Namshin Kim, Beihua Dong, David Boren, Serena A Lee, Jaydip Das Gupta, Christina Gaughan, Eric A Klein, Christopher Lee, Robert H Silverman, Samson A Chow.   

Abstract

Xenotropic murine leukemia virus-related virus (XMRV) is a new human gammaretrovirus identified in prostate cancer tissue from patients homozygous for a reduced-activity variant of the antiviral enzyme RNase L. Neither a casual relationship between XMRV infection and prostate cancer nor a mechanism of tumorigenesis has been established. To determine the integration site preferences of XMRV and the potential risk of proviral insertional mutagenesis, we carried out a genome-wide analysis of viral integration sites in the prostate cell line DU145 after an acute XMRV infection and compared the integration site pattern of XMRV with those found for murine leukemia virus and two human retroviruses, human immunodeficiency virus type 1 and human T-cell leukemia virus type 1. Among all retroviruses analyzed, XMRV has the strongest preference for transcription start sites, CpG islands, DNase-hypersensitive sites, and gene-dense regions; all are features frequently associated with structurally open transcription regulatory regions of a chromosome. Analyses of XMRV integration sites in tissues from prostate cancer patients found a similar preference for the aforementioned chromosomal features. Additionally, XMRV integration sites in cancer tissues were associated with cancer breakpoints, common fragile sites, microRNA, and cancer-related genes, suggesting a selection process that favors certain chromosomal integration sites. In both acutely infected cells and cancer tissues, no common integration site was detected within or near proto-oncogenes or tumor suppressor genes. These results are consistent with a model in which XMRV may contribute to tumorigenicity via a paracrine mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684813      PMCID: PMC2566297          DOI: 10.1128/JVI.01299-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  111 in total

1.  Molecular basis for expression of common and rare fragile sites.

Authors:  Eitan Zlotorynski; Ayelet Rahat; Jennifer Skaug; Neta Ben-Porat; Efrat Ozeri; Ruth Hershberg; Ayala Levi; Stephen W Scherer; Hanah Margalit; Batsheva Kerem
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 2.  Rare fragile sites.

Authors:  G R Sutherland
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

Review 3.  Prostate cancer.

Authors:  William G Nelson; Angelo M De Marzo; William B Isaacs
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

Review 4.  Retroviral insertional mutagenesis: tagging cancer pathways.

Authors:  Harald Mikkers; Anton Berns
Journal:  Adv Cancer Res       Date:  2003       Impact factor: 6.242

5.  RTCGD: retroviral tagged cancer gene database.

Authors:  Keiko Akagi; Takeshi Suzuki; Robert M Stephens; Nancy A Jenkins; Neal G Copeland
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

6.  Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.

Authors:  Hui-Kuan Lin; Yueh-Chiang Hu; Lin Yang; Saleh Altuwaijri; Yen-Ta Chen; Hong-Yo Kang; Chawnshang Chang
Journal:  J Biol Chem       Date:  2003-10-10       Impact factor: 5.157

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

Review 8.  Chromosome aberrations in solid tumors.

Authors:  Donna G Albertson; Colin Collins; Frank McCormick; Joe W Gray
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

9.  Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.

Authors:  Ying Xiang; Zhengfu Wang; Junko Murakami; Sarah Plummer; Eric A Klein; John D Carpten; Jeffrey M Trent; William B Isaacs; Graham Casey; Robert H Silverman
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

10.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

View more
  60 in total

1.  Analysis of single-nucleotide polymorphisms in patient-derived retrovirus integration sites reveals contamination from cell lines acutely infected by xenotropic murine leukemia virus-related virus.

Authors:  Alice Rusmevichientong; Jaydip Das Gupta; Petra S Elias; Robert H Silverman; Samson A Chow
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

Authors:  Jui Pandhare-Dash; Chinmay K Mantri; Yuanying Gong; Zhenbang Chen; Chandravanu Dash
Journal:  Prostate       Date:  2011-09-19       Impact factor: 4.104

3.  Next-generation sequencing of prostate tumors provides independent evidence of xenotropic murine leukemia virus-related gammaretrovirus contamination.

Authors:  Fan Mo; Alexander W Wyatt; Chunxiao Wu; Anna V Lapuk; Marco A Marra; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

4.  Retroviral infection of hES cells produces random-like integration patterns.

Authors:  Kwang-il Lim
Journal:  Mol Cells       Date:  2012-04-20       Impact factor: 5.034

5.  Patients, patience, and the publication process.

Authors:  Randy Schekman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-23       Impact factor: 11.205

6.  Acutely transforming retrovirus expressing Nras generated from HT-1080 fibrosarcoma cells infected with the human retrovirus XMRV.

Authors:  Michael J Metzger; A Dusty Miller
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

7.  The path well traveled: using mammalian retroviruses to guide research on XMRV.

Authors:  KyeongEun Lee; Kathryn S Jones
Journal:  Mol Interv       Date:  2010-02

8.  Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer.

Authors:  Faraz Ahmed Baig; Talat Mirza; Amna Hamid; Serajuddaula Syed; Qamar Jamal
Journal:  Turk J Urol       Date:  2017-07-31

9.  The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.

Authors:  Michael J Metzger; Christiana J Holguin; Ramon Mendoza; A Dusty Miller
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Androgen stimulates transcription and replication of xenotropic murine leukemia virus-related virus.

Authors:  Beihua Dong; Robert H Silverman
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.